CRA consultant Becky Davis was interviewed by Drug Topics at Asembia AXS25 Conference on “Rising Demand, New Indications Put GLP-1s in the Spotlight.”
Davis discussed the expanding potential of GLP-1 receptor agonists, which are being explored for conditions beyond obesity and diabetes, such as Alzheimer’s and Parkinson’s disease. As these medications gain broader indications, she predicts that payers will shift them to standard benefit plans, increasing access but also raising cost pressures. This evolution is expected to create a more competitive market, with manufacturers and insurers needing to adjust accordingly.
